Goldman Sachs Group Inc Compass Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 371,129 shares of CMPX stock, worth $508,446. This represents 0.0% of its overall portfolio holdings.

Number of Shares

371,129

Previous 235,506 57.59%

Holding current value

$508,446

Previous $235,000 190.21%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.88 $108,498 - $254,971	135,623 Added 57.59%	371,129 $682,000
Q2 2024 Aug 13, 2024	BUY	$1.0 - $1.85 $112,794 - $208,668	112,794 Added 91.92%	235,506 $235,000
Q1 2024 May 15, 2024	SELL	$1.2 - $2.29 $100,662 - $192,096	-83,885 Reduced 40.6%	122,712 $242,000
Q4 2023 Feb 13, 2024	SELL	$1.4 - $1.98 $19,019 - $26,898	-13,585 Reduced 6.17%	206,597 $322,000
Q3 2023 May 14, 2024	BUY	$1.87 - $3.25 $25,403 - $44,151	13,585 Added 6.58%	220,182 $433,000
Q3 2023 Nov 14, 2023	BUY	$1.87 - $3.25 $210,610 - $366,034	112,626 Added 104.71%	220,182 $433,000
Q2 2023 May 14, 2024	SELL	$2.64 - $3.48 $240,150 - $316,561	-90,966 Reduced 45.82%	107,556 $342,000
Q2 2023 Aug 14, 2023	SELL	$2.64 - $3.48 $240,150 - $316,561	-90,966 Reduced 45.82%	107,556 $342,000
Q1 2023 May 14, 2024	SELL	$3.14 - $5.48 $25,355 - $44,251	-8,075 Reduced 3.91%	198,522 $649,000
Q1 2023 May 11, 2023	BUY	$3.14 - $5.48 $623,359 - $1.09 Million	198,522 New	198,522 $649,000

Others Institutions Holding CMPX

# of Institutions

Shares Held

91.9M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $139M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Compass Therapeutics, Inc. Transaction History